Sanara MedTech Inc. (NASDAQ: SMTI) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $301M. The Maz Rating grades it against the other companies in its sector.
Sanara MedTech Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.73, Sanara MedTech Inc. trades at 2.7x sales and 37.6x book value, with an EV/EBITDA of 45.3. Over the last twelve months it generated about $112M of revenue and a net loss of $3M. It runs a gross margin of 91.8%, an operating margin of 7.2% and a net margin of -2.7%. It shows return on equity of -42.2%, return on invested capital of 14.3% and a free cash flow yield of 2.4%. On the balance sheet: a debt-to-equity ratio of 6.35 and a current ratio of 2.24. Over the past 52 weeks the share price ranged from $16.05 to $35.52, with a beta of 1.20.
Sanara MedTech Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 2 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Sanara MedTech Inc. (SMTI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 15.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.2% / 30% · Interest income / Revenue 0.52% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 15.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.68% / 33% · Receivables / Mkt Cap (36m) 5.30% / 49% · Interest income / Revenue 0.52% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 15.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.68% / 33.33% · Receivables / Mkt Cap (24m) 5.30% / 33.33% · Interest income / Revenue 0.52% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 65.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 22.0% / 33.33% · Receivables / Avg Assets (4Q) 19.0% / 33.33% · Interest income / Revenue 0.52% / 5% | Fail |
| FTSE | Debt / Total Assets 64.7% / 33.33% · (Cash+ST Inv) / Total Assets 23.2% / 33.33% · (Cash+Recv) / Total Assets 44.9% / 33.33% · Interest income / Revenue 0.52% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Sanara MedTech Inc. (SMTI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Sanara MedTech Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.52% of each dividend: Sanara MedTech Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.